Medicine at the Crick

The session will review the profound opportunities of CAR-T cell therapy, adoptive cellular immunotherapies and checkpoint inhibitor therapy in the management of haematologic and metastatic solid tumours.

These Immunotherapies, by leveraging the patient's immune system, are transforming clinical care, resulting in prolonged survival and even cancer cures in a previously palliative setting. This event will review recent breakthroughs in the field, challenges and opportunities in the translation of scientific findings into the clinic and the promise of leveraging adaptive cellular therapies to tackle cancer clonal evolution for patient benefit.